Why buy this course?

The course you are looking at is not like any other e-Learning course you have ever taken.
Watch this short video to learn why!

FDA Proposed Reclassification of Digital Breast Tomosynthesis (DBT) Systems

$129.99

Stay ahead of regulatory changes impacting breast cancer screening technologies with this targeted course on the FDA’s proposed reclassification of digital breast tomosynthesis (DBT) systems. Learn about the transition from class III (premarket approval) to class II (special controls), the rationale behind the proposed rule, and the impact on device manufacturers, healthcare professionals, and patients. The course provides a detailed look at required special controls, device risks, regulatory background, and the public comment process, equipping you to respond effectively to forthcoming regulatory requirements.

In this course you will learn the following:
* Understand the purpose and intent of the proposed reclassification of DBT systems.
* Describe the regulatory framework for medical device classification.
* Identify the risks associated with DBT systems and the proposed special controls to mitigate them.
* Recognize the process for submitting public comments and the importance of stakeholder participation.
* Explain how the proposed rule may evolve based on feedback and is not yet final.

NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year. At the end of the one year term, the course will be set to “inactive”.

Why This Course is Important
Without this course, you may lack critical knowledge on the new FDA regulatory expectations for DBT systems, potentially missing opportunities for early compliance, streamlined device submissions, and influencing the final rule.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Radiology Devices; Reclassification of Digital Breast Tomosynthesis System.

Key regulatory references include:

Course SKU
FR-26-2144-1

About Benchmarks:

Are you ready for this regulation? Use this benchmark to find out.

Each benchmark is build directly for the federal regulation.  They reflect the learning objectives of the related course.

The benchmark is not a “trivia test” – they help you evaluate your readiness to apply the new regulation.

Contact us for more information and/or personalized benchmarks for your specific organization/industry.

FDA Proposed Reclassification of Digital Breast Tomosynthesis (DBT) Systems

Stay ahead of regulatory changes impacting breast cancer screening technologies with this targeted course on the FDA’s proposed reclassification of digital breast tomosynthesis (DBT) systems. Learn about the transition from class III (premarket approval) to class II (special controls), the rationale behind the proposed rule, and the impact on device manufacturers, healthcare professionals, and patients. The course provides a detailed look at required special controls, device risks, regulatory background, and the public comment process, equipping you to respond effectively to forthcoming regulatory requirements.

In this course you will learn the following:
* Understand the purpose and intent of the proposed reclassification of DBT systems.
* Describe the regulatory framework for medical device classification.
* Identify the risks associated with DBT systems and the proposed special controls to mitigate them.
* Recognize the process for submitting public comments and the importance of stakeholder participation.
* Explain how the proposed rule may evolve based on feedback and is not yet final.

NOTE: Unless otherwise indicated, all Benchmarks are free of charge!

Why This Course is Important
Without this course, you may lack critical knowledge on the new FDA regulatory expectations for DBT systems, potentially missing opportunities for early compliance, streamlined device submissions, and influencing the final rule.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Radiology Devices; Reclassification of Digital Breast Tomosynthesis System.

Key regulatory references include:

Course SKU
FR-26-2144-1

Replenish your Studio Course Advisor Unit balance here . Please contact frsales@courseavenue.com if you need to purchase more. Talk to use about an Enterprise License to see if that is right for you!

FDA Proposed Reclassification of Digital Breast Tomosynthesis (DBT) Systems

$129.99

Why This Course is Important
Without this course, you may lack critical knowledge on the new FDA regulatory expectations for DBT systems, potentially missing opportunities for early compliance, streamlined device submissions, and influencing the final rule.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Radiology Devices; Reclassification of Digital Breast Tomosynthesis System.

Key regulatory references include:

Course SKU
FR-26-2144-1

Stay ahead of regulatory changes impacting breast cancer screening technologies with this targeted course on the FDA’s proposed reclassification of digital breast tomosynthesis (DBT) systems. Learn about the transition from class III (premarket approval) to class II (special controls), the rationale behind the proposed rule, and the impact on device manufacturers, healthcare professionals, and patients. The course provides a detailed look at required special controls, device risks, regulatory background, and the public comment process, equipping you to respond effectively to forthcoming regulatory requirements.

In this course you will learn the following:
* Understand the purpose and intent of the proposed reclassification of DBT systems.
* Describe the regulatory framework for medical device classification.
* Identify the risks associated with DBT systems and the proposed special controls to mitigate them.
* Recognize the process for submitting public comments and the importance of stakeholder participation.
* Explain how the proposed rule may evolve based on feedback and is not yet final.

Related products